Abstract
Background: Recent in vitro studies have indicated that irisin inhibits proliferation, migration and epithelial-mesenchymal transition. Irisin expression has not been studied in tumour tissues of non-small cell lung cancer (NSCLC) patients yet. The aim of the study was to determine the irisin expression in NSCLCs in comparison to the clinicopathological factors and expression of TTF-1, p63 and Ki-67. Material and methods: Tissue microarrays with 729 NSCLC and 140 non-malignant lung tissue (NMLT) were used to perform immunohistochemical reactions. Laser Capture Microdissection (LCM) was used to collect cancer and stromal cells from NSCLCs. FNDC5 expression was tested for LCM samples, 75 NSCLCs and 25 NMLTs with the RT-PCR technique. Western-blot, immunofluorescence reaction and RT-PCR assays were performed on lung cancer cell lines. Results: Irisin expression was observed in NSCLC cancer cells and stromal fibroblasts. In cancer cells, irisin expression was decreased in higher grades (G) of malignancy, tumour size (T) and according to lymph node metastasis. In stromal cells, irisin expression was increased in higher G and advanced T. A shorter overall survival was observed in patients with higher irisin expression in NSCLC stromal cells. Conclusions: Irisin expression in stromal fibroblasts may influence cancer cell proliferation and may be a prognostic factor for survival in NSCLC.
Highlights
Non-small cell lung cancer (NSCLC), which accounts for 80% of all lung cancers, is still one of the tumours with the worst prognosis
Our study indicates that the expression of irisin in stromal fibroblasts may be associated with an increased proliferation of cancer cells and may be an independent prognostic factor for survival in patients with non-small cell lung cancer (NSCLC)
We observed for the first time an elevated level of irisin expression in cancer cells and tumour stromal fibroblasts in tumour tissues of NSCLC patients
Summary
Non-small cell lung cancer (NSCLC), which accounts for 80% of all lung cancers, is still one of the tumours with the worst prognosis. Cancers 2019, 11, 1538 recent studies have revealed that irisin could be such a marker, the expression of which was observed in NSCLCs in our study. Irisin expression has not been studied in tumour tissues of non-small cell lung cancer (NSCLC) patients yet. Material and methods: Tissue microarrays with 729 NSCLC and 140 non-malignant lung tissue (NMLT) were used to perform immunohistochemical reactions. Was used to collect cancer and stromal cells from NSCLCs. FNDC5 expression was tested for LCM samples, 75 NSCLCs and 25 NMLTs with the RT-PCR technique. Results: Irisin expression was observed in NSCLC cancer cells and stromal fibroblasts. Irisin expression was decreased in higher grades (G) of malignancy, tumour size (T) and according to lymph node metastasis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
